Cytochromes P450: Roles in the biotransformation of chemicals in cigarette smoke and impact of smoking cessation on concurrent drug therapy

Journal of Smoking Cessation

Volumn 5, Issue 2, 2010, Pages 107-114

  Murray, Michael ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Chemical carcinogens; Cytochrome P450; Gene activation; Metabolic oxidation; Nicotine biotransformation

Indexed keywords

EID: 79952218555     PISSN: None     EISSN: 18342612     Source Type: Journal    
DOI: 10.1375/jsc.5.2.107     Document Type: Article

References (37)

1. Bachmann, K., Shapiro, R., Fulton, R., Carroll, F.T., & Sullivan, T.J. (1979) Smoking and warfarin disposition. Clinical Pharmacology & Therapeutics, 25(3), 309-315.
2. Beale, M.D., Pritchett, J.T., & Kellner, C.H. (1994) Supraventricular tachycardia in a patient receiving ECT, clozapine, and caffeine. Journal of ECT, 10(3), 228-231.
3. Bertilsson, L., Carrillo, J.A., Dahl, M.L., Llerena, A., Alm, C., Bondesson, U., et al. (1994) Clozapine disposition covaries with CYP1A2 activity determined by a caffeine test. British Journal of Clinical Pharmacology, 38(5), 471-473.
4. Bjeldanes, L.F., Kim, J.Y., Grose, K.R., Bartholomew, J.C., & Bradfield, C.A. (1991) Aromatic hydrocarbon responsiveness-receptor agonists generated from indole-3-carbinol in vitro and in vivo: Comparisons with 2,3,7,8-tetrachlorodibenzo-p-dioxin. Proceedings of the National Academy of Sciences USA, 88(21), 9543-9547.
5. Bondolfi, G., Morel, F., Cretto, S., Rachid, F., Baumann, P., & Eap, C.B. (2005) Increased clozapine plasma concentrations and side effects induced by smoking cessation in 2 CYP1A2 genotyped patients. Therapeutic Drug Monitoring, 27(4), 539-543.
6. Carlson, D.B., & Perdew, G.H. (2002) A dynamic role for the Ah receptor in cell signaling? Insights from a diverse group of Ah receptor interacting proteins. Journal of Biochemical & Molecular Toxicology,16(6), 317-325.
7. Colucci, V.J., & Knapp, J.F. (2001) Increase in international normalized ratio associated with smoking cessation. Annals of Pharmacotherapy, 35(3), 385-386.
8. de Leon, J., Armstrong, S.C., & Cozza, K.L. (2005) The dosing of atypical antipsychotics. Psychosomatics, 46(3), 262-273.
9. Dodick, D.W., & Martin, V. (2004) Triptans and CNS side effects: pharmacokinetics and metabolic mechanisms. Cephalalgia, 24(6), 417-424.
10. Faber, M.S., & Fuhr, U. (2004) Time response of cytochrome P450 1A2 activity on cessation of heavy smoking. Clinical Pharmacology & Therapeutics, 76(2), 178-184.
11. Freeman, D.J., & Oyewumi, L.K. (1997) Will routine therapeutic drug monitoring have a place in clozapine therapy? Clinical Pharmacokinetics, 32(2), 93-100.
12. Guengerich, F.P. (1988) Roles of cytochrome P-450 enzymes in chemical carcinogenesis and cancer chemotherapy. Cancer Research, 48(11), 2946-2954.
13. Guengerich, F.P. (2005) Human cytochrome P450 enzymes. In P.R. Ortiz de Montellano (Ed.), Cytochrome P450: Structure, mechanism, and biochemistry (pp. 377-530). New York: Kluwer Academic/Plenum.
14. Guengerich, F.P., Kim, D.H., & Iwasaki, M. (1991) Role of human cytochrome P450 IIE1 in the oxidation of many low molecular weight cancer suspects. Chemical Research in Toxicology, 4(2), 168-179.
15. Hanawalt, P.C. (2001) Controlling the efficiency of excision repair, Mutation Research, 485(1), 3-13.
16. Hankinson, O. (1995) The aryl hydrocarbon receptor complex. Annual Review of Pharmacology & Toxicology, 35, 307-340.
17. Hecht, S.S. (1998) Biochemistry, biology, and carcinogenicity of tobacco-specific N-nitrosamines. Chemical Research in Toxicology, 11(6), 559-603.
18. Hecht, S.S. (1999) Tobacco smoke carcinogens and lung cancer. Jounrnal of the National Cancer Institute, 91(14), 1194-1210.
19. Hukkanen, J., Jacob, III, P., & Benowitz, N.L. (2005) Metabolism and disposition kinetics of nicotine. Pharmacological Reviews, 57(1), 79-115.
20. Kaminsky, L.S., & Zhang, Z.-Y. (1997) Human P450 metabolism of warfarin. Pharmacology & Therapeutics, 73(1), 67-74.
21. Kassahun, K., Mattiuz, E., Nyhart, Jr, E., Obermeyer, B., Gillespie, T., Murphy, A. et al. (1997) Disposition and biotransformation of the antipsychotic agent olanzapine in humans. Drug Metabolism & Disposition, 25(1), 81-93.
22. Lee, B.L., Benowitz, N.L., & Jacob, III, P. (1987) Cigarette abstinence, nicotine gum, and theophylline disposition. Annals of Internal Medicine, 106(4), 553-555.
23. McCarthy, R.H. (1994) Seizures following smoking cessation in a clozapine responder. Pharmacopsychiatry, 27(5), 210-211.
24. Meyer, J.M. (2001) Individual changes in clozapine levels after smoking cessation: Results and a predictive model. Journal of Clinical Psychopharmacology, 21(6), 569-574.
25. Norbury, C.J., & Hickson, I.D. (2001) Cellular responses to DNA damage. Annual Review of Pharmacology& Toxicology, 41, 367-401.
26. Odom-White, A., & de Leon, J. (1996) Clozapine levels and caffeine. Journal of Clinical Psychiatry, 57(4), 175-176.
27. Olesen, O.V. (1998) Therapeutic drug monitoring of clozapine treatment: therapeutic threshold value for serum clozapine concentrations. Clinical Pharmacokinetics, 34(6), 497-502.
28. Özdemir, V., Kalow, W., Okey, A.B., Lam, M.S.M., Albers, L.J., Reist, C. et al. (2001) Treatment-resistance to clozapine in association with ultrarapid CYP1A2 activity and the C>A polymorphism in intron 1 of the CYP1A2 gene: Effect of grapefruit juice and low-dose fluvoxamine. Journal of Clinical Psychopharmacology, 21(6), 603-607.
29. Pianezza, M.L., Sellers, E.M., & Tyndale, R.F. (1998). Nicotine metabolism defect reduces smoking. Nature, 393(6687), 750.
30. Raunio, H., Rautio, A., Gullstén, H., & Pelkonen, O. (2001) Polymorphisms of CYP2A6 and its practical consequences. British Journal of Clinical Pharmacology, 52(4), 357-363.
31. Sellers, E.M., Kaplan, H.L., & Tyndale, R.F. (2000) Inhibition of cytochrome P450 2A6 increases nicotine's oral bioavailability and decreases smoking. Clinical Pharmacology & Therapeutics, 68(1), 35-43.
32. Shimada, T., Yun, C.H., Yamazaki, H., Gautier, J.C., Beaune, P.H., & Guengerich, F.P. (1992) Characterization of human lung microsomal cytochrome P-450 1A1 and its role in the oxidation of chemical carcinogens. Molecular Pharmacology, 41(5), 856-864.
33. Simpson, G.M., & Cooper, T.A. (1978) Clozapine plasma levels and convulsions. American Journal of Psychiatry, 135(1), 99-100.
34. Skogh, E., Bengtsson, F., & Nordin, C. (1999) Could discontinuing smoking be hazardous for patients administered clozapine medication? A case report. Therapeutic Drug Monitoring, 21(5), 580.
35. Statland, B.E., & Demas, T.J. (1980) Serum caffeine half-lives. Healthy subjects vs. patients having alcoholic hepatic disease. American Journal of Clinical Pathology, 73(3), 390-393.
36. Tang, D., Phillips, D.H., Stampfer, M., Mooney, L.A., Hsu, Y., Cho, S., et al. (2001) Association between carcinogen-DNA adducts in white blood cells and lung cancer risk in the physicians health study. Cancer Research, 61 (18), 6708-6712.
37. Zevin, S., & Benowitz, N.L. (1999) Drug interactions with tobacco smoking: An update. Clinical Pharmacokinetics, 36(6), 425-438.